July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Infliximab for the successful treatment of uveitis failing adalimumab.
Author Affiliations & Notes
  • Noy Ashkenazy
    Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas, United States
  • Ujwala Saboo
    Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas, United States
  • Ashley Abraham
    Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas, United States
  • Cristiana Ronconi
    Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas, United States
  • Graham Kuizin
    Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas, United States
  • Jennifer Cao
    Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas, United States
  • Footnotes
    Commercial Relationships   Noy Ashkenazy, None; Ujwala Saboo, None; Ashley Abraham, None; Cristiana Ronconi, None; Graham Kuizin, None; Jennifer Cao, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 406. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Noy Ashkenazy, Ujwala Saboo, Ashley Abraham, Cristiana Ronconi, Graham Kuizin, Jennifer Cao; Infliximab for the successful treatment of uveitis failing adalimumab.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):406.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine if infliximab can be successfully used to achieve steroid-free remission in patients who have failed adalimumab.

Methods : A retrospective chart review was performed on uveitis patients treated with infliximab after failing adalimumab at the University of Texas Southwestern Medical School in Dallas, TX, between Sept 2015 and Sept 2016. Demographics, comorbidities, site and severity of uveitis, duration of therapy, visual acuity, and side effects were reviewed. Statistical analysis was performed using SPSS 24.0 (Chicago, IL).

Results : Twelve subjects, 2 adults and 10 children (age range 7-78) were identified to have been switched to infliximab infusions after failing to achieve steroid-free remission on adalimumab. There was a 100% response rate to infliximab, and 3(25%) subjects achieved steroid-free remission. Age, gender, and ethnicity were not statistically significant determinants of steroid-free remission in our cohort. There was a higher rate of remission in patients with anterior uveitis (p=0.007), in patients with associated systemic manifestations (p=0.018) as opposed to inflammation isolated to the eye only, and in the absence of retinal vasculitis (p=0.091).

Conclusions : To our knowledge, this is the first study to describe the use of infliximab in the context of adalimumab failure. Twenty-five percent of our study achieved steroid-free remission. Larger, long-term systematic studies are necessary to confirm our findings.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×